Baxter International Inc. has projected its 2026 adjusted profit to be between $1.85 and $2.05 per share, significantly below analysts' average expectation of $2.25 per share. This substantial miss on market consensus highlights potential operational headwinds. The medical products maker attributed this lower forecast primarily to the ongoing impact of hurricane-related disruptions at a crucial manufacturing unit. Following the announcement, the company's shares experienced a sharp decline, dropping 14% in premarket trading. This strong negative market reaction underscores investor concerns regarding Baxter's near-term profitability and operational stability.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis